ledipasvir/sofosbuvir / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 54 Diseases   8 Trials   8 Trials   2662 News 


12345678910111213...2324»
  • ||||||||||  Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma, sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
    Journal:  Attitudes and perspectives of healthcare workers on treating chronic hepatitis C infection in children and adolescents. (Pubmed Central) -  Feb 7, 2025   
    These were also reported to be the most commonly available drug regimens at respondents' facilities. This survey provides insights from a heterogenous sample of HCWs from across the world with respect to their expressed priorities and preferences for the treatment of children and adolescents with chronic HCV.
  • ||||||||||  prednisone / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
    Journal:  Minimal change disease in treatment-na (Pubmed Central) -  Jan 16, 2025   
    The nephrotic syndrome remained in remission 24 months after initial presentation. This is a unique case where sustained remission of both the nephrotic syndrome and the HCV infection were achieved with glucocorticoids and direct antiviral agents, respectively.
  • ||||||||||  Valcyte (valganciclovir) / Roche, Mitsubishi Tanabe, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    Management of HCV-Infection in Pediatric Patients Undergoing HCT: A Single-Center Experience () -  Dec 7, 2024 - Abstract #ASH2024ASH_9409;    
    One patient received a reduced-intensity conditioning regimen consisting of fludarabine + cyclophosphamide...DAAs were started after discontinuation of immunosuppressive therapy, for 4/5 patients.The combination of drugs used was : glecaprevir + pibrentasvir (2 patients), sofosbuvir + velpatasvir and ledipasvir + sofosbuvir...Two patients developed CMV-reactivation and required pre-emptive therapy with valganciclovir...No data are currently available regarding the possibility of viral reactivation in patients receiving treatment before transplant. Larger studies are needed to assess the right timing of treatment based on clinical evaluations.
  • ||||||||||  Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    Journal:  Assessing the Efficacy of Novel Antiviral Therapies in Treating Hepatitis C. (Pubmed Central) -  Nov 25, 2024   
    Larger studies are needed to assess the right timing of treatment based on clinical evaluations. Patients were divided among mild, advanced, and post-liver transplant as 320 (64%), 150 (30%), and 30 (6%), respectively.
  • ||||||||||  ledipasvir/sofosbuvir / Generic mfg., methadone / Generic mfg.
    Journal:  Experience and challenges delivering hepatitis C virus treatment for people who inject drugs in Kenya. (Pubmed Central) -  Nov 5, 2024   
    Challenges faced while delivering HCV treatment at participating sites included the limited availability and reliability of laboratory assays, and financial constraints faced by PWIDs to attend daily DOT. Based on our experience, strategies to deliver HCV treatment for PWID in Kenya should consider improving the availability of laboratory tests and prioritizing treatment through methadone centers to achieve good outcomes.
  • ||||||||||  Journal:  Table 3: Some drug interactions with DAAs for HCV infection. (Pubmed Central) -  Oct 28, 2024   
    Based on our experience, strategies to deliver HCV treatment for PWID in Kenya should consider improving the availability of laboratory tests and prioritizing treatment through methadone centers to achieve good outcomes. No abstract available
  • ||||||||||  Zepatier (grazoprevir/elbasvir) / Merck (MSD), Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Technivie (ombitasvir/paritaprevir/ritonavir) / AbbVie
    HCV cure with direct?acting antivirals in HIV/HCV coinfected patients belonging to key populations () -  Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_536;    
    The SVR rates were similar in PLH infected by sexual mode or in PWIDs, irrespective of the CD4 cell count or HIV-VL. Elimination of HCV requires a targeted scale-up of DAA treatment and behavioural interventions in particular among high-risk populations.
  • ||||||||||  Xiannuoxin (simnotrelvir) / Simcere, Shanghai Inst. of Materia Medica, Crixivan (indinavir sulfate) / Merck (MSD), Isentress (raltegravir) / Merck (MSD)
    Journal:  Evaluation of inhibition effect and interaction mechanism of antiviral drugs on main protease of novel coronavirus: Molecular docking and molecular dynamics studies. (Pubmed Central) -  Oct 19, 2024   
    The interaction mechanism between antiviral drugs and main protease was analyzed in detail by calculating the root mean square displacement (RMSD), root mean square fluctuation (RMSF) and interaction residues properties. The results showed that the six drugs with high flexibility (Remdesivir, Simnotrelvir, Sofosbuvir, Ledipasvir, Indinavir and Raltegravir) had strong binding strength with 3CLpro, and the last four antiviral drugs can be used as potential candidates for main protease inhibitors.
  • ||||||||||  Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    MEDICARE PART D COVERAGE RESTRICTIONS FOR DRUGS COMMONLY PRESCRIBED FOR HEPATITIS C TREATMENT, 2019-2024 () -  Oct 15, 2024 - Abstract #AASLD2024AASLD_2420;    
    Over the years, a higher proportion of plans imposed quantity limits for brand name hepatitis C formulations. With our findings, we highlight the need for urgent advocacy, legislative efforts, and policy initiatives to ensure affordable, equitable, and timely access to treatment for Part D beneficiaries with Hepatitis C.
  • ||||||||||  ledipasvir/sofosbuvir / Generic mfg.
    HEPATITIS C MANAGEMENT OF WOMEN IN THE THIRD TRIMESTER OF PREGNANCY IN LA BODEGA () -  Oct 15, 2024 - Abstract #AASLD2024AASLD_1234;    
    Using a test and treat model for pregnant women actively using drugs improves HCV treatment starts, SVR rates, and reduces vertical transmission. Third-trimester HCV therapy can also help initiate MAT for those actively using substances.
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
    EVALUATION OF HEPATITIS C TREATMENT AND CARE MODEL IN PRIMARY HEALTHCARE CENTERS IN THE COUNTRY OF GEORGIA () -  Oct 15, 2024 - Abstract #AASLD2024AASLD_1213;    
    Our analysis shows the effectiveness of integrating a simplified HCV diagnosis and treatment model in PHCs. Countrywide expansion of this model is warranted to bridge the gaps in the hepatitis C care continuum and ensure high rates of treatment uptake, enabling Georgia to achieve hepatitis C elimination.
  • ||||||||||  Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    Trends in Prescriber Characteristics of Hepatitis C Direct-Acting Antivirals in the United States (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_5130;    
    Between 2015 and 2021, 102,767 Medicare patients received DAAs. The annual number of patients receiving DAAs decreased from 45,697 in 2015 to 3,633 in 2021 (2015-2017: APC -50.7, 95% CI -57.4 to -39.4, p< 0.001; 2017-2021: APC -25.6, 95% CI -30.8 to -13.9, p< 0.001).
  • ||||||||||  ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
    Journal:  Hepatitis C virus diversity and treatment outcomes in Benin: a (Pubmed Central) -  Jul 4, 2024   
    This study revealed a high SVR rate in Benin among individuals treated for HCV with sofosbuvir-velpatasvir, including those with highly diverse viral genotypes. Further studies of treatment effectiveness in genotypes 2d and 2b are indicated.
  • ||||||||||  Zepatier (grazoprevir/elbasvir) / Merck (MSD), Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    Modeling suggests that undetectable HCV at week 2 of DAA therapy could identify patients for shorter treatment duration (Poster Area) -  Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_1245;    
    Mathematical modeling of in silico patients that reach undetectable HCV by day 14 predicted that >90% cure rates could be achieved with 4-5 weeks of DAA therapy. This RGT could improve treatment access, facilitate HCV elimination, and reduce cost, particularly in patient groups most affected by HCV such as PWID.
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
    Evaluation of hepatitis C treatment and care model in primary healthcare centers in the country of Georgia (Poster Area) -  Apr 2, 2024 - Abstract #EASLILC2024EASL_ILC_749;    
    Our analysis shows the effectiveness of integrating a simplified HCV diagnosis and treatment model in PHCs. Countrywide expansion of this model is warranted to bridge the gaps in the hepatitis C care continuum and ensure high rates of treatment uptake, enabling Georgia to achieve hepatitis C elimination.
  • ||||||||||  Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    TRENDS IN MEDICAID SPENDING FOR HEPATITIS C TREATMENT FROM 2012-2021 (Hall A, Poster Hall - Walter E. Washington Convention Center) -  Mar 14, 2024 - Abstract #DDW2024DDW_6920;    
    The highest spending was noted to be with originator medications while generic formulations had the highest number of claims. Understanding the trends in spending on HCV medications can help guide insurance coverage changes for those depending on Medicaid.
  • ||||||||||  ivermectin oral / Generic mfg.
    DRUGS USED FOR COVID-19, IMPLICATIONS TO THE RENAL FUNCTION, AND PROSPECTS (TUE-092; Main Foyer) -  Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_984;    
    Medicines used without proof may have had negative consequences for the population, not just by the nephrologic diseases, but to the other areas of health, including the drop in supply. Furthermore, research has evolved to reduce mortality rates through the most diverse pharmacological routes, however, the only safe way to combat the disease still remains prevention.
  • ||||||||||  Zepatier (grazoprevir/elbasvir) / Merck (MSD), Vosevi (sofosbuvir/velpatasvir/voxilaprevir) / Gilead, Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    Journal:  ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource-limited settings. (Pubmed Central) -  Feb 19, 2024   
    The World Health Organization has set the ambitious target to eliminate hepatitis C as a major public health threat by 2030 and based its actions against HCV on the large use of direct acting antivirals. These updated European Society for Pediatric Gastroenterology, Hepatology and Nutrition recommendations on treatment of hepatitis C describe the optimal therapeutic management of adolescents and children with HCV infection including specific indications for those living in resource-limited settings.
  • ||||||||||  ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
    Efficacy of Sofosbuvir, Velpatasvir and Ribavirin in prior DAA experienced patients in Myanmar (New Hall) -  Jan 20, 2024 - Abstract #APASL2024APASL_2633;    
    Background: Treatment options for DAA experienced hepatitis C patients are limited in Myanmar as Sofosbuvir, Velpatasvir, Voxilaprevir regimen and Glecaprevir and Pibrentasvir regimens are not available...Seventeen patients received prior treatment with Sofosbuvir and Daclatasvir, one with Sofosbuvir and Ledipasvir and two with SOF/VEL regimen...One patient had HBV co-infection and three had HIV taking Tenofovir/Lamivudine/Dolutegravir... SOF/VEL/RBV regimen for 24 weeks is effective in difficult-to-treat DAA experienced patients and is a feasible option in a resource limited country like Myanmar.
  • ||||||||||  ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
    Complications of RFA: Challenges to Treatment with the collective efforts of the Gastroenterology. (New Hall) -  Jan 6, 2024 - Abstract #APASL2024APASL_2227;    
    The prognosis for complications of local ablation therapy can be improved by the concerted efforts of the gastroenterology department. Further efforts to prevent complications and avoid serious complications through early detection are necessary.